AU757139B2 - Methods of hydrating mucosal surfaces - Google Patents

Methods of hydrating mucosal surfaces Download PDF

Info

Publication number
AU757139B2
AU757139B2 AU12141/00A AU1214100A AU757139B2 AU 757139 B2 AU757139 B2 AU 757139B2 AU 12141/00 A AU12141/00 A AU 12141/00A AU 1214100 A AU1214100 A AU 1214100A AU 757139 B2 AU757139 B2 AU 757139B2
Authority
AU
Australia
Prior art keywords
loweralkyl
group
phenyl
carrier moiety
absorbable carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU12141/00A
Other languages
English (en)
Other versions
AU1214100A (en
Inventor
Richard C. Boucher Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU1214100A publication Critical patent/AU1214100A/en
Application granted granted Critical
Publication of AU757139B2 publication Critical patent/AU757139B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AU12141/00A 1998-10-20 1999-10-20 Methods of hydrating mucosal surfaces Ceased AU757139B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10499998P 1998-10-20 1998-10-20
US60/104999 1998-10-20
PCT/US1999/024546 WO2000023023A1 (en) 1998-10-20 1999-10-20 Methods of hydrating mucosal surfaces

Publications (2)

Publication Number Publication Date
AU1214100A AU1214100A (en) 2000-05-08
AU757139B2 true AU757139B2 (en) 2003-02-06

Family

ID=22303527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12141/00A Ceased AU757139B2 (en) 1998-10-20 1999-10-20 Methods of hydrating mucosal surfaces

Country Status (8)

Country Link
US (2) US6264975B1 (enExample)
EP (1) EP1143896B1 (enExample)
JP (1) JP2002527459A (enExample)
AT (1) ATE347880T1 (enExample)
AU (1) AU757139B2 (enExample)
CA (1) CA2346656A1 (enExample)
DE (1) DE69934435T2 (enExample)
WO (1) WO2000023023A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264975B1 (en) * 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
ATE390414T1 (de) * 1999-07-19 2008-04-15 Univ North Carolina Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
WO2003038089A1 (fr) * 2001-11-02 2003-05-08 Ngk Insulators, Ltd. Compositions de solution de sonde, puce reactive faisant appel auxdites compositions et son procede de production
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
AU2003291151A1 (en) * 2002-11-22 2004-06-18 Carnegie Mellon University Compositions and methods for the reversible capture of biomolecules
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
GB0303506D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
WO2004089423A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene theraphy of epithelial sodium channel associated disoders
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7705036B2 (en) 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
CA2561733A1 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CA2575670A1 (en) * 2004-08-18 2006-03-02 Michael R. Johnson Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US8692002B2 (en) 2004-11-18 2014-04-08 Cardiome Pharma Corp. Synthetic process for aminocyclohexyl ether compounds
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
JP5159616B2 (ja) 2005-06-15 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
EP2019964A2 (en) * 2006-04-28 2009-02-04 University of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection. method to identify a viral receptor or co-receptor
WO2008031048A2 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
AU2007294547A1 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
FI119513B (fi) 2007-03-07 2008-12-15 Dextech Medical Ab Muokatut hydroksipolymeerikonjugaatit, joilla on tappava vaikutus tuumorisoluihin
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
US20110118207A1 (en) * 2008-04-07 2011-05-19 Dextech Medical Ab Modified hydroxypolymer conjugates with bone seeking and tumor killing moieties
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9452198B2 (en) 2012-04-23 2016-09-27 Massachusetts Institute Of Technology Lectin conjugates for mucin hydration
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
EP3137084B1 (en) * 2014-05-02 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Benzyl amiloride for the treatment of psoriasis
US9675667B2 (en) 2015-02-10 2017-06-13 Massachusetts Institute Of Technology Isolated mucins and different microorganisms, and methods of use
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
EP4585274A3 (en) 2020-04-13 2025-09-17 Mayo Foundation for Medical Education and Research Electroporation devices and methods
US20220047686A1 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods for treating infectious diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299931A (enExample) * 1962-10-30
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6032714A (ja) 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US4950591A (en) * 1987-08-14 1990-08-21 Cherksey Bruce D Membrane Na+ channel protein and related therapeutic compounds
US4894376A (en) 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
JPH0678315B2 (ja) * 1988-04-28 1994-10-05 シェリング・コーポレーション 新規なベンゾピリド‐ピペリジン、ピペリジリデンおよびピペラジン化合物、組成物、製造法および利用法
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
CA2266898A1 (en) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Co., Inc. Intranasal formulations for promoting sleep and method of using the same
US6264975B1 (en) * 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Also Published As

Publication number Publication date
EP1143896A4 (en) 2004-11-24
AU1214100A (en) 2000-05-08
ATE347880T1 (de) 2007-01-15
US6264975B1 (en) 2001-07-24
DE69934435T2 (de) 2007-09-27
DE69934435D1 (de) 2007-01-25
CA2346656A1 (en) 2000-04-27
EP1143896A1 (en) 2001-10-17
EP1143896B1 (en) 2006-12-13
JP2002527459A (ja) 2002-08-27
WO2000023023A1 (en) 2000-04-27
US7056524B2 (en) 2006-06-06
US20010034349A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
EP1143896B1 (en) Methods of hydrating the nasal mucosal surface
EP0831777B1 (en) Dinucleotides useful for the treatment of lung disease
AU774865B2 (en) Conjugates of sodium channel blockers and methods of using the same
US7981898B2 (en) Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
CN105073717B (zh) 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
TW200817343A (en) Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
AU9124998A (en) Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases
JP2007502827A (ja) 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
EP0941099B1 (en) Treatment of bronchitis with diuridine tetraphosphate
CN101534813A (zh) 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
PT1594500E (pt) Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas
CN103153315A (zh) 用吸入地纽福索治疗囊性纤维化的方法
WO2004098581A2 (en) Oral spray to reduce cold symptoms and duration of same
HK1017843A (en) Dinucleotides useful for the treatment of lung disease
HK1089380B (en) Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
HK1034464A (en) Novel pharmaceutical compositions of uridine triphosphate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)